Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
03:17:45 EDT Wed 08 May 2024
Enter Symbol
or Name
USA
CA



Q:BLUE - BLUEBIRD BIO INC - http://www.bluebirdbio.com/
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
BLUE - Q3.00.99·1.030.91.01+0.011.03,550.83,3995,4681.03  1.06  0.98015.53  0.851May 07May 0615 min RT 2¢

Recent Trades - Last 10 of 5468
Time ETExPriceChangeVolume
19:31:45Q1.02980.029870
19:30:19Q1.00070.00071
19:30:13Q1.00 1
19:25:58Q1.00080.0008319
19:17:12Q1.010.01374
19:13:58Q1.00 2
18:45:48Q1.010.0115
18:41:57Q1.010.0141,497
18:29:28Q1.030.031,000
18:29:27Q1.030.031,000

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-05-06 07:05U:BLUENews Releasebluebird bio Announces First Quarter 2024 Results Call Date and Upcoming Investor Events
2024-05-06 07:00U:BLUENews Releasebluebird bio Announces Completion of First Cell Collection for LYFGENIA(TM) Gene Therapy
2024-04-26 16:05U:BLUENews Releasebluebird bio Announces Receipt of Expected Notice from Nasdaq
2024-04-11 08:00U:BLUENews Releasebluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-03-26 07:01U:BLUENews Releasebluebird bio Reports Fourth Quarter and 2023 Annual Results and Highlights Operational Progress and 2024 Guidance
2024-03-25 16:05U:BLUENews Releasebluebird bio to Host Fourth Quarter and 2023 Annual Results Conference Call
2024-03-18 08:00U:BLUENews Releasebluebird bio Secures up to $175 Million Debt Financing with Hercules Capital
2024-03-11 08:00U:BLUENews Releasebluebird bio Announces First Outcomes-Based Agreement with Medicaid for Sickle Cell Disease Gene Therapy
2024-01-08 08:00U:BLUENews Releasebluebird bio Provides Update on Commercial Launch Progress, Program Milestones, and 2024 Financial Outlook
2024-01-02 08:00U:BLUENews Releasebluebird bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-19 21:41U:BLUENews Releasebluebird bio, Inc. Announces Pricing of $125 Million Public Offering of Common Stock
2023-12-18 16:01U:BLUENews Releasebluebird bio, Inc. Announces Proposed Public Offering of Common Stock
2023-12-10 12:02U:BLUENews ReleaseLong-Term Data Presented at ASH Support beti-cel as a Potentially Curative Gene Therapy for Ž ²-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels
2023-12-09 11:31U:BLUENews ReleaseLong-term Follow-up Data From bluebird ¢ € ™s Gene Therapy Program in Sickle Cell Disease Support Durable, Potentially Curative Benefits Through Stable Production of Anti-Sickling Adult Hemoglobin and Resolution of Vaso-Occlusive Events
2023-12-08 13:01U:BLUENews Releasebluebird bio Details Plans for the Commercial Launch of LYFGENIA ¢ „ ¢ Gene Therapy for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events
2023-12-08 12:35U:BLUENews Releasebluebird bio Announces FDA Approval of LYFGENIA ¢ „ ¢ (lovotibeglogene autotemcel) for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events
2023-11-07 07:00U:BLUENews Releasebluebird bio Reports Third Quarter 2023 Financial Results and Highlights Operational Progress
2023-11-02 09:37U:BLUENews Releasebluebird bio to Present New and Updated Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition
2023-10-30 08:00U:BLUENews Releasebluebird bio Enters into Advance Agreement to Sell Priority Review Voucher, if Granted, for $103 Million
2023-10-24 08:00U:BLUENews Releasebluebird bio to Host Third Quarter 2023 Financial Results Conference Call